Monday, April 29, 2024

10:00 AM – 5:00 PM ET
Registration

5:30 PM – 7:30 PM ET
Reception

Tuesday, April 30, 2024

8:00 AM – 5:00 PM ET
Registration

8:00 AM – 5:00 PM ET
Poster Viewing and Networking

8:00 AM – 9:00 AM ET
Breakfast

9:00 AM – 9:45 AM ET
Welcome and Opening Keynote: Shifting the Paradigm to Push Past Limits
Advocates are dramatically altering the landscape of rare research and reducing the timeline for rare disease therapy development. What is it that allows some organizations to move faster, be more nimble, use resources effectively and blaze new paths? Is there a matrix that can help you determine what will work for you?

• Charlene Son Rigby, CEO, Global Genes
• Tania Simoncelli, Vice President, Science in Society, Chan Zuckerburg Initiative

9:45 AM - 10:30 AM ET
Session 1: The Critical Need for Patient-Led Data Initiatives: Does Size Matter?
Researchers and regulators need data. But what kind? Who is the end user? What is “enough data?” Do you need certain types of data for specific research projects? Why? Most importantly how do you evaluate your data set to be certain it’s useful?

• Moderator: Zohreh Talebizadeh, Ph.D., Senior Director, RARE-X Research Program, Global Genes
• Ramona Walls, Ph.D., Executive Director of Data Science, C-Path
• Ben Forred, Director, The CoRDS Registry, Sanford Health
• Dave Jacoby, M.D., Ph.D., BioMarin Fellow in Clinical Science & Vice President, Head of Discovery Medicine, Brineura/BioMarin

10:30 AM – 10:45 AM ET
Morning Break

10:45 AM – 11:45 AM ET
Interactive Groups on Patient-Led Data Initiatives
Potential topics include patient identification, types of data (genotype/phenotype, biomarker, outcome measure, etc.); combining data sets; use of data for disease modeling, progression and insights on therapeutic target; and strategies for registries, natural history studies, biobanks and cell lines.
12:00 PM - 1:00 PM ET
Lunch with GAA Networking

1:00 PM - 2:00 PM ET
Expert Office Hours (By Appointment Only)
Get answers to your questions by scheduling a one-to-one session with one of our experts on topics such as data collection, research strategy, therapy development and engaging with the FDA. For available appointments, please check with the Global Genes staff at the registration desk.

2:15 PM - 3:00 PM ET
Session 2: Rethinking Clinical Trials: What’s Doable? What’s Approvable?
Researchers are overcoming barriers posed by small populations using decentralized and basket trials, platform science, wearables, videos, natural history data and engaging diverse patients. But what does FDA guidance say? Are the regulatory constraints different? How can patient communities prepare by ensuring their data is well-structured?

  • Moderator: Katherine Maynard, Partner, PWR
  • Jennifer Farmer, CEO, Friedreich’s Ataxia Research Alliance
  • Manoj Malhotra, M.D., Chief Medical Officer, Ovid Therapeutics
  • Cynthia Rothblum-Oviatt, Ph.D., External Engagement Lead for FDA’s Rare Diseases Team, U.S. Food & Drug Administration (FDA)

3:00 PM – 3:15 PM ET
Afternoon Break

3:15 PM – 4:15 PM ET
Interactive Groups on Rethinking Clinical Trials
Potential topics include remote clinical trials, perpetual clinical trial platforms, using natural history data in lieu of placebos, use of avatars, effective and equitable communication between patients and researchers, platform science, N of 1 and accrual of patients for gene therapy....

4:30 PM – 5:30 PM ET
Expert Office Hours (By Appointment Only)
Get answers to your questions by scheduling a one-to-one session with one of our experts on topics such as data collection, research strategy, therapy development and engaging with the FDA. For available appointments, please check with the Global Genes staff at the registration desk.

5:30 PM – 8:00 PM ET
Welcome Reception

Network:
Sheraton_Meeting
Password:
RDDS2024
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 4:00 PM ET</td>
<td><strong>Registration</strong></td>
</tr>
<tr>
<td>8:00 AM – 3:00 PM ET</td>
<td><strong>Poster Viewing and Networking</strong></td>
</tr>
<tr>
<td>8:00 AM – 9:00 AM ET</td>
<td><strong>Breakfast</strong></td>
</tr>
<tr>
<td>9:00 AM – 9:15 AM ET</td>
<td><strong>Welcome and Opening Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Wrap up from yesterday and preparing for today's sessions</td>
</tr>
<tr>
<td></td>
<td>• Charlene Son Rigby, CEO, Global Genes</td>
</tr>
<tr>
<td></td>
<td>You've raised some money and have a strategy (or are about to develop one). The next question is, “What will your funds realistically buy for your organization?” Are there creative ways to make the most of what you have? How do you choose partners and negotiate?</td>
</tr>
<tr>
<td></td>
<td>• <strong>Moderator:</strong> Karmen Trzupek, Senior Director, Scientific Programs, Global Genes</td>
</tr>
<tr>
<td></td>
<td>• Betty Cabrera, Director of Research Engagement &amp; Operations, UC San Diego Gene Therapy Initiative</td>
</tr>
<tr>
<td></td>
<td>• Casey McPherson, CEO, To Cure A Rose Foundation</td>
</tr>
<tr>
<td></td>
<td>• Ashley Winslow, Ph.D., CEO &amp; CSO, Odylia Therapeutics</td>
</tr>
<tr>
<td>10:15 AM – 10:30 AM ET</td>
<td><strong>Morning Break</strong></td>
</tr>
<tr>
<td>10:30 AM – 11:30 AM ET</td>
<td><strong>Interactive Groups on Emerging Commercial and Non-Profit Financing Models</strong></td>
</tr>
<tr>
<td></td>
<td>Potential topics include using your money to jumpstart a project or combine with other funding sources, non-profit biotechs, public benefit corporations, N of 1 and cost comparison for various tools.</td>
</tr>
<tr>
<td>11:30 AM – 1:00 PM ET</td>
<td><strong>Lunch with Table Topics</strong></td>
</tr>
<tr>
<td>1:00 PM - 2:30 PM ET</td>
<td><strong>Session 4: Rare Resource Fair</strong></td>
</tr>
<tr>
<td></td>
<td>Whether you're creating a research strategy - or putting an existing one into action, this session will help you build knowledge, ask providers of products and services the questions you have about your specific situation, and make informed decisions on which companies you want to work with. If you're new to research, you can request a mentor at the registration desk to guide you through the fair.</td>
</tr>
<tr>
<td>2:30 PM – 2:45 PM ET</td>
<td><strong>Afternoon Break</strong></td>
</tr>
</tbody>
</table>
Closing Keynote and Remarks
What new solutions are emerging to accelerate translational research in rare disease? What can patients, caregivers, researchers and organizations do to help move the needle? In this ‘Fireside Chat’, you’ll learn how Dominique Pichard’s unique experience as a physician, rare Mom and advocate has informed her approach to leading innovation in rare disease research at NCATS.

- Charlene Son Rigby, CEO, Global Genes
- Dominique Pichard, M.D., Director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
Thank You to our Sponsors

GOLD

sanofi

SILVER

ALEXION®
AstraZeneca Rare Disease

AMGEN Rare Disease

TRAVERE THERAPEUTICS

ueb
Inspired by patients. Driven by science.

BRONZE

biocryst™
bridgebio

PARTNER

Amicus Therapeutics

Chiesi global rare diseases

Crinetics Pharmaceuticals

Ovid Therapeutics

Spark Therapeutics